Kapsch D N, Adelstein E H, Rhodes G R, Silver D
Surgery. 1979 Jul;86(1):148-55.
Twenty-two patients developed significant thrombocytopenia (5,000 to 96,000/cu mm; mean, 29,000/cu mm) while receiving prophylactic or therapeutic heparin. Seventeen of them developed serious thrombohemorrhagic complications which accelerated the deaths of six and contributed to the late death of one. Cessation of heparin therapy led to an immediate remission of the thrombohemorrhagic complications and thrombocytopenia, with no patient who was not already moribund dying, once appropriate therapy had been instituted. Platelet-count monitoring is recommended for all patients receiving heparin for more than 6 days, with cessation of heparin therapy mandatory for the successful management of patients with this disorder. Evidence is presented for an immunologic etiology for this disorder.
22名患者在接受预防性或治疗性肝素治疗时出现了显著的血小板减少（5000至96000/立方毫米；平均29000/立方毫米）。其中17名患者出现了严重的血栓出血并发症，加速了6人的死亡，并导致1人晚期死亡。停止肝素治疗后，血栓出血并发症和血小板减少立即缓解，一旦采取了适当的治疗措施，没有一名尚未濒死的患者死亡。建议对所有接受肝素治疗超过6天的患者进行血小板计数监测，对于成功治疗这种疾病的患者，必须停止肝素治疗。本文提供了该疾病免疫病因学的证据。
